{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-005501","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.370377+00:00","generated_at":"2026-06-24T02:19:58.705258+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MiNK Q2 net loss $6.1M; cash $29.8M; DARPA selects AgenT-797; clinical data updates expected 2H22","bullets":["Cash $29.8M as of June 30, 2022, down from $38.9M at Dec 31, 2021; cash used in ops $4.6M for Q2.","Net loss $6.1M ($0.18/share) vs $6.3M ($0.26/share) in Q2 2021; R&D spend $5.9M vs $3.6M.","AgenT-797 clinical data updates in solid tumors, myeloma and viral ARDS planned for 2H2022.","AgenT-797 identified as selectable for DARPA funding; contract negotiations underway.","Internal cGMP manufacturing completed with capacity to treat >700,000 patients/year; Dr. Joy Zhou appointed VP CMC."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-005501","json":"https://secwatch.observer/filing/0001171843-22-005501.json","markdown":"https://secwatch.observer/filing/0001171843-22-005501.md","text":"https://secwatch.observer/filing/0001171843-22-005501.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000117184322005501/0001171843-22-005501-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000117184322005501/f8k_080922.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:19:58.705258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}